들이마신 경우,호흡이 어려운 경우 환자를 신선한 공기가 있는 곳으로 옮기고 호흡하기 편한 자세로 안정을 취하게 함
P321
(…) 처치를 하시오.
P333+P313
피부자극성 또는 홍반이 나타나면 의학적인 조치·조언를 구하시오.
P342+P311
호흡기 증상이 나타나면 의료기관(의사)의 진찰을 받으시오.
P363
다시 사용전 오염된 의류는 세척하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
Cefozopran C화학적 특성, 용도, 생산
화학적 성질
White To Pale-Yellow Powder
용도
Antibacterial
Antimicrobial activity
An aminothiazole cephalosporin formulated as the hydrochloride.
Activity is similar to that of ceftazidime, but it is more
active against methicillin-susceptible staphylococci (MIC 1
mg/L). Representative MICs against Gram-negative species
are: Esch coli 0.25 mg/L; K. pneumoniae 1 mg/L; Ps. aeruginosa
1–8 mg/L. Activity against Acinetobacter spp., Sten. maltophilia
and B. fragilis group is poor.
A 20-min infusion of 1.5 g achieved a plasma concentration
of around 125 mg/L at the end of infusion. Almost 90%
of the dose was excreted in the urine over 24 h. The mean terminal
half-life was around 2 h. Adverse reactions appear to be
typical of those of other group 6 cephalosporins.
It is available in Japan.
